A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY)
Sponsor: Pfizer
A PHASE3 clinical study on Urinary Bladder, Neurogenic, this trial is completed. The trial is conducted by Pfizer and has accumulated 42 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
42 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 37 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Completed PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Completed PHASE3
-
May 2020 — Jul 2020 [monthly]
Completed PHASE3
-
Apr 2020 — May 2020 [monthly]
Completed PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Atlanta, United States , Basel, Switzerland , Batu Caves, Malaysia , Bratislava, Slovakia , Bron, France , Brussels, Belgium , Bunkyo-ku, Japan , Cagliari, Italy , Cape Town, South Africa and 56 more locations